2011
DOI: 10.1016/j.critrevonc.2011.01.012
|View full text |Cite
|
Sign up to set email alerts
|

Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999–2009)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
32
0

Year Published

2013
2013
2020
2020

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 35 publications
(33 citation statements)
references
References 122 publications
0
32
0
Order By: Relevance
“…111 In is a common γ-emitting radionuclide used in the clinic for SPECT imaging [26]. 90 Y as a beta emitting radionuclide has been clinically used for radiotherapeutic treatment of tumors [27]. 111 In and 90 Y have similar half-lives (2.80 and 2.67 days, respectively) that correspond to the potential biological half-life of HPMA copolymer construct.…”
Section: Resultsmentioning
confidence: 99%
“…111 In is a common γ-emitting radionuclide used in the clinic for SPECT imaging [26]. 90 Y as a beta emitting radionuclide has been clinically used for radiotherapeutic treatment of tumors [27]. 111 In and 90 Y have similar half-lives (2.80 and 2.67 days, respectively) that correspond to the potential biological half-life of HPMA copolymer construct.…”
Section: Resultsmentioning
confidence: 99%
“…High-energy radiation from 90 Y-loaded microspheres, locally injected via catheterization, is used to destroy active tumor cells [1][2][3][4]. As an almost pure electron emitter, 90 Y has a number of attractive characteristics, for example its long half-life of 64.2 h and a high mean (max) particle energy of 0.94 MeV (2.28 MeV) [5].…”
mentioning
confidence: 99%
“…Lipiodol has been labelled with iodine-131 (Liebster and Kocandrle, 1964;Raoul et al, 1986), rhenium-188 (Lepareur et al, 2008), yttrium-90 (Wang et al, 1996b;Yu et al, 2003), and radiolanthanides (Das et al, 2009;Subramanian et al, 2010). Yttrium-90 (pure beta-emitter, E β max ¼2.27 MeV, t 1/2 ¼64 h, max tissue penetration¼ 12 mm) has ideal properties for targeted radiotherapy, and has found wide use in peptide receptor radionuclide therapy (Goffredo et al, 2011), radioimmunotherapy (Sharkey et al, 2010) and radioembolisation (Salem and Hunter, 2006). It has been suggested as a suitable isotope to label Lipiodol as it should lead to a significantly reduced whole-body dose compared to 131 I-Lipiodol, since more than 90% of this dose is due to the emitted gamma rays (respectively Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/apradiso 0.02 rad/mCi compared to 1.9 rad/mCi, based on estimated dosimetry) (Madsen et al, 1988).…”
Section: Introductionmentioning
confidence: 98%